Tafenoquine in two Phase III trials for Malaria - GSK
GlaxoSmithKline has announced the start of a Phase III global programme to evaluate the efficacy and safety of tafenoquine for the treatment of and relapse prevention (radical cure) of Plasmodium vivax (P. vivax) Malaria. The Phase III programme includes two randomised, double-blind treatment studies to investigate tafenoquine in adult patients with P. vivax malaria.
The DETECTIVE study (TAF112582) aims to evaluate the efficacy, safety and tolerability of tafenoquine as a radical cure for P. vivax malaria, co-administered with chloroquine, a blood stage anti-malarial treatment. The GATHER study (TAF116564) aims to assess the incidence of hemolysis and safety and efficacy of tafenoquine compared to primaquine, the only approved treatment currently available for the radical cure of P. vivax malaria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins